dc.contributor.author | Hodges, N | |
dc.contributor.author | Battersby, N | |
dc.contributor.author | Rao, S | |
dc.contributor.author | Brown, G | |
dc.contributor.author | TRIGGER Study Group | |
dc.coverage.spatial | United States | |
dc.date.accessioned | 2022-09-15T09:11:29Z | |
dc.date.available | 2022-09-15T09:11:29Z | |
dc.date.issued | 2022-06-30 | |
dc.identifier | 10.1245/s10434-022-11914-5 | |
dc.identifier.citation | Annals of Surgical Oncology, 2022, | |
dc.identifier.issn | 1068-9265 | |
dc.identifier.uri | https://repository.icr.ac.uk/handle/internal/5482 | |
dc.identifier.eissn | 1534-4681 | |
dc.identifier.eissn | 1534-4681 | |
dc.identifier.doi | 10.1245/s10434-022-11914-5 | |
dc.description.abstract | BACKGROUND: It is widely believed that small rectal tumors are more likely to have a good response to neoadjuvant treatment, which may influence the selection of patients for a 'watch and wait' strategy. OBJECTIVE: The aim of this study was to investigate whether there is a relationship between baseline tumor length on magnetic resonance imaging (MRI) and response to chemoradiotherapy. METHOD: The 96 patients with locally advanced rectal cancer randomised (2:1-intervention:control) in the TRIGGER feasibility study where eligible. Baseline tumor length was defined as the maximal cranio-caudal length on baseline MRI (mm) and was recorded prospectively at study registration. Magnetic resonance tumor regression grade (mrTRG) assessment was performed on the post-chemoradiotherapy (CRT) MRI 4-6 weeks (no later than 10 weeks) post completion of CRT. This was routinely reported for patients in the intervention (mrTRG-directed management) arm and reported for the purposes of this study by the central radiologist in the control arm patients. Those with an mrTRG I/II response were defined as 'good responders' and those with an mrTRG III-V response were defined as 'poor responders'. RESULTS: Overall, 94 patients had a post-CRT MRI performed and were included. Forty-three (46%) patients had a good response (mrTRG I/II) and 51 (54%) patients had a poor response (mrTRG III/IV). The median tumor length of good responders was 43 mm versus 50 mm (p < 0.001), with considerable overlap in tumor lengths between groups. CONCLUSION: Baseline tumor length on MRI is not a clinically useful biomarker to predict mrTRG tumor response to CRT and therefore patient suitability for a deferral of surgery trial. | |
dc.format | Print-Electronic | |
dc.language | eng | |
dc.language.iso | eng | |
dc.publisher | SPRINGER | |
dc.relation.ispartof | Annals of Surgical Oncology | |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | |
dc.subject | TRIGGER Study Group | |
dc.title | Relationship Between Baseline Rectal Tumor Length and Magnetic Resonance Tumor Regression Grade Response to Chemoradiotherapy: A Subanalysis of the TRIGGER Feasibility Study. | |
dc.type | Journal Article | |
dcterms.dateAccepted | 2022-05-03 | |
dc.date.updated | 2022-09-15T09:10:35Z | |
rioxxterms.version | NA | |
rioxxterms.versionofrecord | 10.1245/s10434-022-11914-5 | |
rioxxterms.licenseref.startdate | 2022-06-30 | |
rioxxterms.type | Journal Article/Review | |
pubs.author-url | https://www.ncbi.nlm.nih.gov/pubmed/35771366 | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Medicine (RMH Smith Cunningham) | |
pubs.organisational-group | /ICR/Primary Group/Royal Marsden Clinical Units | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Medicine (RMH Smith Cunningham)/Medicine (RMH Smith Cunningham) (hon.) | |
pubs.publication-status | Published online | |
pubs.publisher-url | http://dx.doi.org/10.1245/s10434-022-11914-5 | |
icr.provenance | Deposited by Mr Arek Surman on 2022-09-15. Deposit type is initial. No. of files: 1. Files: s10434-022-11914-5.pdf | |